Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET

Inclusion Criteria: * Patients with normal ovarian function reserve (5 ≤ AFC ≤ 15, 1.2 ng/ml ≤ AMH ≤ 3.5 ng/ml). * Patients with regular menstrual cycle (21-35 days) and normal ovulation. * Initial IVF / ICSI treatment. * At least one embryo or blastocyst available for transfer. Exclusion Criteria: * Age ≥ 43 years old. * Body mass index (BMI) ≥ 28 Kg/m2. * "Freeze-all" strategy. * Those using the natural cycle or mild stimulation for IVF/ICSI treatment. * Individuals with severe hyperstimulation ovarian syndrome during controlled ovarian stimulation. * Acceptors of donated oocytes or performed either In vitro Maturation (IVM) or blastocyst biopsy for Preimplantation Genetic Diagnosis (PGD) or Preimplantation Genetic Testing for Aneuploidies (PGT-A). * History of two or more previous consecutive spontaneous abortions. * History of two or more previous IVF-ET failures. * Karyotype abnormalities. * Polycystic ovary syndrome. * Presence of a non-surgically treated hydrosalpinx, uterine cavity fluid or endometrial polyp and an ovarian endometriosis cyst requiring surgery, during ovarian stimulation. * Congenital or acquired abnormalities of uterine anatomy. * Combined contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormalities of liver and kidney function, diabetes mellitus (glycosylated haemoglobin ≤7%, fasting blood glucose \<10 mmol/L ), hypertension, thyroid disease, symptomatic heart disease, moderate to severe anaemia, history o…